Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia

Table 9 Scenario analysis: time horizon

	FDC tablet solifenacin 6 mg + TOCAS vs tolterodine + tamsulosin
	1 year	3 years	5 years	10 years
Cost difference* (£)	−99	26	223	404
QALY difference*	0.002	0.011	0.017	0.018
ICER*^‡	Dominant (−£40,469)	£2,351	£13,531	£22,224

*Per patient.
^‡FDC tablet solifenacin 6 mg + TOCAS versus tolterodine + tamsulosin.
FDC, fixed-dose combination; ICER, incremental cost effectiveness ratio; QALY, quality of life adjusted years; TOCAS, oral controlled absorption system (OCAS™) formulation of tamsulosin.

ISSN: 1471-2490